MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1684759

Медицинская библиотека · Frontiers in immunology · 2025

Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative driver genes.

Sun Liwei, Chen Bonian, Wang Bin, Li Jinduo, Li Lin, Tian Caijuan, Zhang Hongbo, Liu Pengfei, Liu Xiaomin

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

This study aimed to evaluate the efficacy of immunotherapy combined with anti-angiogenic therapy for non-small cell lung cancer (NSCLC) with brain metastasis (BM) and negative driver genes.

METHODS

This observational prospective study was conducted using the clinical data of 34 patients with NSCLC and BM, including 24 patients who received immunotherapy combined with anti-angiogenic therapy and 10 control patients using oral anlotinib upon the first- to fourth-line treatment failure or refusing to continue chemotherapy between June 2017 and August 2022. Efficacy was evaluated using progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions.

RESULTS

Among 24 patients treated with immunotherapy combined with anti-angiogenic therapy, 17 had a partial response, six had stable disease, and one had progressive disease. The ORR and DCR of patients receiving immunotherapy combined with anti-angiogenic therapy were 70.8% and 95.8%, respectively. The median PFS of immunotherapy combined with anti-angiogenic treatment was significantly longer than that of oral anlotinib (18.0 vs. 4 months, log-rank test, p < 0.0001), indicating that immunotherapy combined with anti-angiogenic therapy can substantially improve the treatment efficacy for NSCLC with BM and negative driver genes. Adverse reactions mainly included rash in one case and hypothyroidism in one case, but did not involve myocardial damage or liver and kidney function damage.

CONCLUSION

Immunotherapy combined with anti-angiogenic therapy in patients with recurrent or refractory NSCLC and BM driven by negative genes has yielded promising but preliminary findings.

CLINICAL TRIAL REGISTRATION: www.chictr.org.cn, identifier ChiCTR1800017499.

Для цитирования: Sun Liwei, Chen Bonian, Wang Bin, Li Jinduo, Li Lin, Tian Caijuan, Zhang Hongbo, Liu Pengfei, Liu Xiaomin. Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative driver genes.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1684759.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.